Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease

Gut

Volumn 59, Issue 9, 2010, Pages 1245-1251

  Parkes, Julie ^a   Roderick, Paul ^a   Harris, Scott ^a   Day, Christopher ^b   Mutimer, David ^c   Collier, Jane ^d   Lombard, Martin ^e   Alexander, Graeme ^f   Ramage, John ^g   Dusheiko, Geoffrey ^h   Wheatley, Mark ^a   Gough, Carol ⁱ   Burt, Alastair ^b   Rosenberg, William ^j  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^f CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^h ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

ⁱ WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHRONIC LIVER DISEASE; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL; ADOLESCENT; AGED; BIOPSY; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; EPIDEMIOLOGY; EVALUATION STUDY; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; YOUNG ADULT;

BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY; CHRONIC DISEASE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; YOUNG ADULT;

EID: 77956110546     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.203166     Document Type: Article

References (29)

1. Friedman SL. Liver fibrosisdfrom bench to bedside. J Hepatol 2003;38(Suppl 1): S38-53.
2. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-31. (Pubitemid 41772537)
3. Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003;38:257-65.
4. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
5. Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005;41:257-64.
6. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704-13.
7. Parkes J, Guha I N, Roderick P, et al. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C (p). J Viral Hep Published online: 23 Feb 2010. doi:10.1111/j.1365-2893.2009.01263.x.
8. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple marker. Hepatology 2008;47:455-60.
9. Mayo MJ, Parkes J, Adams-Huet B, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis (ELF) assay. Hepatology 2008;48:1549-57.
10. Nobili V, Parkes J, Bottazzo G, et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009;136:160-7.
11. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36. (Pubitemid 12142173)
12. Kamath PS, Wiesner RH, Malinchoc M, et al. A Model to Predict Survival in Patients with End-Stage Liver Disease. Hepatology 2001;33:464-70.
13. Korner T, Kropf J, Gressner AM. Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. J Hepatol 1996;25:684-8.
14. Guechot J, Serfaty L, Bonnand AM, et al. Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol 2000;32:447-52.
15. Ngo Y, Munteanu M, Messous D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006;52:1887-96.
16. Ngo Y, Benhamou Y, Thibault V, et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS One 2008;3:e2573.
17. Naveau S, Gaudé G, Asnacios A, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009;49:97-105.
18. Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol 2008;32(6 Suppl 1):22-39.
19. Yu M-L, Lin S-M, Lee C-M, et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology 2006;44:1086-97.
20. Rosenberg WM. Rating fibrosis progression in chronic liver diseases. J Hepatol 2003;38:357-60.
21. Christensen E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores - where are we and where should we go? J Hepatol 2006;41:344-50.
22. Mulherin SA, Miller WC. Spectrum bias or spectrum effect? Subgroup variation in diagnostic test evaluation. Ann Intern Med 2002;137:598-602.
23. Goehring C, Perrier A, Morabia A. Spectrum bias: a quantitative and graphical analysis of the variability of medical diagnostic test performance. Stat Med 2004;23:125-35.
24. Thompson CJ, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess 2007;11:1-206.
25. Chalasani N, Boyer TD. Primary prophylaxis against variceal bleeding: beta-blockers, endoscopic ligation, or both? Am J Gastroenterol 2005;100:805-7. (Pubitemid 40592369)
26. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14.
27. Sweeting MJ, De Angelis D, Brant LJ, et al. The burden of hepatitis C in England. J Viral Hepat 2007;14:570-6.
28. Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain, 1950 to 2002. Lancet 2006;367:645.
29. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-55.